Axovant's Cupboard Is Bare After Lead Dementia Program Fails
'New year, new me' is a mantra to be adopted by Swiss drug developer Axovant as it seeks new products to fill its pipeline. The CNS-focused company is floundering having ended development of its lead compound intepirdine following another clinical trial failure.
You may also be interested in...
The Danish group put the 5-HT6 antagonist on the shelf after three failed late-stage trials but Denovo believes that idalopirdine could still work for a subset of Alzheimer's patients.
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.